ASH 2018 | THINK trial: Phase I results for NKG2D CAR-T therapy in AML

David Sallman

CYAD-01 is a CAR T-cell product based on the Natural Killer Group 2D (NKG2D) receptor. Here, David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the latest data presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the Phase I dose escalation THINK trial (NCT03018405), assessing the safety and clinical activity of multiple CYAD-01 administrations without prior preconditioning.

Share this video